beta

ACIU

AC Immune SA

Aciu

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Market Cap: 565 Million

Primary Exchange: NASDAQ

Website: http://www.acimmune.com

Shares Outstanding: 67.6 Million

Float: 33.3 Million

Dividend: (%)

Beta: 0.509605766231797

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Animal testing

Longest drawdown: 818 trading days

From: 2016-09-28 To: 2019-12-10

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud